Edgepark expands diabetes offerings with two new product innovations

Explore the latest in diabetes management solutions, including over-the-counter offerings and first-of-their-kind products

TWINSBURG, Ohio, July 15, 2025 /PRNewswire/ -- Edgepark has recently expanded its portfolio to include the latest innovations from diabetes manufacturers, including the first-ever FDA-cleared yearlong continuous glucose monitor (CGM) system, and a glucose biosensor that can be purchased without a prescription.  

"Our goal is to meet patients where they are in their health journey," said Anthony Alvarez, SVP and GM of Edgepark. "Diabetes is one of the fastest-growing conditions in the United States, and the introduction of innovations like a one-year wearable system and blood glucose biosensors that can be used without a prescription will no doubt play a pivotal role in the well-being of the patients we serve."

Updates to the Edgepark diabetes product portfolio

Biosensor technology: Dexcom Stelo Glucose Biosensor™ System (Stelo)

The first-ever FDA-cleared over-the-counter glucose biosensor, the Dexcom Stelo, is now available through Edgepark, one of the limited number of suppliers to offer it. This biosensor represents a significant leap in glucose monitoring by expanding access to this technology for adults not on insulin and who don't have a history of problematic hypoglycemia. Its groundbreaking accessibility, coupled with the ability to provide glucose insights directly to a smartphone without fingersticks, empowers a wider population to proactively understand and manage their metabolic health. This product is FSA/HSA eligible and can be ordered without a prescription from a healthcare provider here.

"While CGMs have become more accessible through insurance in recent years, there are still many people who do not qualify for coverage – that's where over-the-counter options like the Stelo biosensor come into play," said Alvarez. "At Edgepark, we are laser-focused on overcoming accessibility challenges to help patients manage overall health and make more proactive decisions throughout their day."

New CGM addition: Eversense^® 365 Continuous Glucose Monitoring (CGM)  

Now available through Edgepark, Eversense 365 is the first and only FDA-cleared one-year implantable CGM system, intended for use in those living with Type 1 or Type 2 diabetes who are 18 and older. Most CGM devices are small, wearable sensors that sit on the exterior of the body, lasting around two weeks. The Eversense 365 CGM is inserted only once a year into the upper arm by a health care provider to provide continuous monitoring for 365 days. The system is comprised of three main components:

• An implantable fluorescence-based glucose sensor. Because it rests under the skin, it is less likely to be knocked off.
• A removable smart transmitter that can be taken off and on without requiring a new CGM
• A mobile app that displays glucose data

This new CGM introduces a novel approach to continuous glucose monitoring. Eversense 365's extended-wear duration reduces potential "wearable fatigue" that can be associated with frequent replacements required by traditional CGM devices. Those interested in exploring this as an option for their care journey can click here.

To learn more about the Edgepark diabetes portfolio and explore all available products, visit the Edgepark website.  

About Edgepark

Edgepark is a leading provider of supplies direct-to-home, committed to caring and providing patients solutions that make it easy to choose and receive the products needed to live their best life. Learn more at Edgepark.com.

Media Contact: [email protected]

SOURCE Edgepark Medical Supplies